Abstract
Emergence of multidrug-resistant Gram-negative nosocomial pathogens has led to resurgence of colistin use. Safety and efficacy data regarding colistin use in pediatric patients are sparse, while optimal dosage has not been defined. We present a case series of neonates and children without cystic fibrosis treated with various doses of colistin intravenously. The records of patients who received colistin in a tertiary-care hospital from January 2007 to March 2009 were reviewed. Thirteen patients (median age 5 years, range 22 days to 14 years) received 19 courses of colistin as treatment of pneumonia, central nervous system infection, bacteremia, or complicated soft tissue infection. The isolated pathogens were Acinetobacter baumannii, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. Daily dose of colistin (colistimethate) ranged between 40,000 and 225,000 IU/kg. Duration of administration ranged from 1 to 133 days. Other antimicrobials were co-administered in 18/19 courses. Increase of serum creatinine in one patient was associated with co-administration of colistin and gentamicin. Sixteen of 19 courses had a favorable outcome, and only two of the three deaths were infection-related. Colistin intravenous administration appears well tolerated even at higher than previously recommended doses and of prolonged duration.
Similar content being viewed by others
References
Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. doi:10.1086/595011
Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing: Nineteenth informational supplement. CLSI, Wayne
Dalgic N, Ceylan Y, Sancar M et al (2009) Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Ann Trop Paediatr 29:141–147. doi:10.1179/146532809X440761
Falagas ME, Bliziotis IA, Kasiakou SK et al (2005) Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 5:24. doi:10.1186/1471-2334-5-24
Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. doi:10.1086/429323
Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27. doi:10.1186/cc3995
Falagas ME, Rizos M, Bliziotis IA et al (2005) Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 5:1. doi:10.1186/1471-2334-5-1
Falagas ME, Sideri G, Vouloumanou EK et al (2009) Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 28:123–127. doi:10.1097/INF.0b013e31818a5dbd
Falagas ME, Vouloumanou EK, Rafailidis PI (2009) Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 33(503):e1–e13. doi:10.1016/j.ijantimicag.2008.10.021
Fernandez-Viladrich P, Corbella X et al (1999) Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 28:916–917. doi:10.1086/517243
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118. doi:10.1086/374337
Garner JS, Jarvis WR, Emori TG et al (1996) CDC definitions for nosocomial infections. In: Olmsted RN, Olmsted RN (eds) APIC infection control and applied epidemiology principles and practice. Mosby, St. Louis, pp A-1–A-20
Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 52:813–821. doi:10.1128/AAC.01169-07
Goverman J, Weber JM, Keaney TJ, Sheridan RL (2007) Intravenous colistin for the treatment of multi-drug resistant, Gram-negative infection in the pediatric burn population. J Burn Care Res 28:421–426. doi:10.1097/BCR.0B013E318053D346
Gump WC, Walsh JW (2005) Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 102:915–917. doi:10.3171/jns.2005.102.5.0915
Isturiz R (2008) Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 32:S201–S206. doi:10.1016/S0924-8579(09)70003-2
Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ et al (2002) Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21:212–214. doi:10.1007/s10096-001-0680-2
Kasiakou SK, Michalopoulos A, Soteriades ES et al (2005) Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49:3136–3146. doi:10.1128/AAC.49.8.3136-3146.2005
Katragkou A, Roilides E (2005) Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol 43:4916–4917. doi:10.1128/JCM.43.9.4916-4917.2005
Landman D, Georgescu C, Martin DA, Quale J (2008) Polymyxins revisited. Clin Microbiol Rev 21:449–465. doi:10.1128/CMR.00006-08
Lee SY, Lee JW, Jeong DC et al (2008) Multidrug-Acinetobacter meningitis in a 3-year-old boy treated with i.v. colistin. Pediatr Int 50:584–585. doi:10.1111/j.1442-200X.2008.02677.x
Levin AS, Barone AA, Penco J et al (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28:1008–1011. doi:10.1086/514732
Li J (2005) Difficulty in assaying colistin methanesulphonate. Clin Microbiol Infect 11:773–774. doi:10.1111/j.1469-0691.2005.01218.x
Li J, Coulthard K, Milne R, Nation RL et al (2003) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987–992. doi:10.1093/jac/dkg468
Li J, Nation RL, Turnidge JD et al (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601. doi:10.1016/S1473-3099(06)70580-1
Linden PK, Kusne S, Coley K et al (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37:e154–e160. doi:10.1086/379611
Markou N, Apostolakos H, Koumoudiou C et al (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7:R78–R83. doi:10.1186/cc2358
Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK (2006) Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 58:1078–1081. doi:10.1093/jac/dkl347
Nunn SL, Wellman WE (1960) Pseudomonas meningitis: report of a case. Med Clin North Am 44:1075–1078
Petrosillo N, Ioannidou E, Falagas ME (2008) Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14:816–827. doi:10.1111/j.1469-0691.2008.02061.x
Pintado V, San Miguel LG, Grill F, Mejia B et al (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 56:185–190. doi:10.1016/j.jinf.2008.01.003
Pitout JD (2008) Multiresistant enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 6:657–669. doi:10.1586/14787210.6.5.657
Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436. doi:10.1128/AAC.01361-08
Pournaras S, Protonotariou E, Voulgari E et al (2009) Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 64:348–352. doi:10.1093/jac/dkp207
Price DJ, Sleigh JD (1972) Klebsiella meningitis–report of nine cases. J Neurol Neurosurg Psychiatry 35:903–908
Reina R, Estenssoro E, Saenz G et al (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065. doi:10.1007/s00134-005-2691-4
Rosanova M, Epelbaum C, Noman A et al (2009) Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res 30:612–615. doi:10.1097/BCR.0b013e3181abffb6
Schina M, Spyridi E, Daoudakis M et al (2006) Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with intravenous and intrathecal colistin. Int J Infect Dis 10:178–179. doi:10.1016/j.ijid.2005.03.005
Souli M, Galani I, Giamarellou H (2008) Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13:19045
Swift PN, Bushby SR (1951) Haemophilus influenza meningitis treated with polymyxin. Lancet 2:183–190
Tamma PD, Lee CK (2009) Use of colistin in children. Pediatr Infect Dis J 28:534–5. doi:10.1097/INF.0b013e3181ac4980
Weinbren MJ (1999) Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44:319–327. doi:10.1093/jac/44.3.319
Acknowledgements
EI was recipient of a research grant from the Hellenic National Institute of Scholarships.
Conflict of interest
None of the authors have any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iosifidis, E., Antachopoulos, C., Ioannidou, M. et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 169, 867–874 (2010). https://doi.org/10.1007/s00431-009-1137-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-009-1137-3